CY1122615T1 - Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου - Google Patents

Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου

Info

Publication number
CY1122615T1
CY1122615T1 CY20191100753T CY191100753T CY1122615T1 CY 1122615 T1 CY1122615 T1 CY 1122615T1 CY 20191100753 T CY20191100753 T CY 20191100753T CY 191100753 T CY191100753 T CY 191100753T CY 1122615 T1 CY1122615 T1 CY 1122615T1
Authority
CY
Cyprus
Prior art keywords
stem cells
endometrial
endometrium
therapy
diseases
Prior art date
Application number
CY20191100753T
Other languages
Greek (el)
English (en)
Inventor
Carlos SIMÓN
Javier SANTAMARIA
Antonio PELLICER
Irene CERVELLO
Original Assignee
Igenomix S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenomix S.L. filed Critical Igenomix S.L.
Publication of CY1122615T1 publication Critical patent/CY1122615T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
CY20191100753T 2014-06-17 2019-07-16 Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου CY1122615T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462013121P 2014-06-17 2014-06-17
PCT/IB2015/001715 WO2015193737A1 (en) 2014-06-17 2015-06-05 Stem cell therapy in endometrial pathologies

Publications (1)

Publication Number Publication Date
CY1122615T1 true CY1122615T1 (el) 2021-03-12

Family

ID=54329860

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100753T CY1122615T1 (el) 2014-06-17 2019-07-16 Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου
CY20221100258T CY1125938T1 (el) 2014-06-17 2022-04-05 Θεραπεια με βλαστοκυτταρα σε παθολογιες του ενδομητριου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20221100258T CY1125938T1 (el) 2014-06-17 2022-04-05 Θεραπεια με βλαστοκυτταρα σε παθολογιες του ενδομητριου

Country Status (22)

Country Link
US (1) US11129851B2 (enExample)
EP (3) EP3158057B1 (enExample)
JP (2) JP6920062B2 (enExample)
CN (2) CN116747241A (enExample)
AU (1) AU2015275798B2 (enExample)
BR (1) BR112016029558A2 (enExample)
CA (1) CA2952559C (enExample)
CY (2) CY1122615T1 (enExample)
DK (2) DK3158057T3 (enExample)
ES (3) ES2983444T3 (enExample)
HR (3) HRP20220419T1 (enExample)
HU (3) HUE044823T2 (enExample)
LT (2) LT3569697T (enExample)
MX (1) MX377300B (enExample)
PL (3) PL3158057T3 (enExample)
PT (2) PT3569697T (enExample)
RS (3) RS63093B1 (enExample)
RU (1) RU2725006C2 (enExample)
SI (2) SI3158057T1 (enExample)
SM (3) SMT202200155T1 (enExample)
TR (1) TR201910410T4 (enExample)
WO (1) WO2015193737A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
AU2013273242B2 (en) 2012-06-06 2019-04-11 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
ES2906586T3 (es) 2012-10-12 2022-04-19 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
SMT202200155T1 (it) 2014-06-17 2022-05-12 Asherman Therapy S L Terapia con cellule staminali in patologie endometriali
EP3474866A4 (en) * 2016-06-23 2020-02-26 Tithon Biotech, Inc. CELLS EXPRESSING THE PARATHYROID HORMONE RECEPTOR 1 AND USES THEREOF
RU2699029C1 (ru) * 2018-12-10 2019-09-03 Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке
RU2741621C1 (ru) * 2020-09-25 2021-01-28 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения внутриматочных синехий
KR20230015832A (ko) 2021-07-23 2023-01-31 차의과학대학교 산학협력단 분리된 미토콘드리아를 유효성분으로 포함하는 아셔만 증후군 예방 또는 치료용 약학 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2054197A1 (en) 1989-05-05 1990-11-06 Christopher O'neill Fertility enhancement
US6979533B2 (en) 1992-06-12 2005-12-27 The Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
CA2203718A1 (en) 1997-04-25 1998-10-25 University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
AU2001240096A1 (en) 2000-03-08 2001-09-17 Rebecca L. Dubowy Methods of diagnosing and monitoring endometrial glandular development
EP1301195A2 (en) 2000-05-24 2003-04-16 Schering Aktiengesellschaft Pharmaceutical use of fibulin-1
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
AUPR673001A0 (en) 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
DE10139874A1 (de) 2001-08-10 2003-04-30 Schering Ag Humane Mater-Proteine
GB0201284D0 (en) 2002-01-21 2002-03-06 Isis Innovation Screening methods for contraceptive and fertility agents
US20030186300A1 (en) 2002-03-20 2003-10-02 Ali Akoum Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions
US20040005612A1 (en) 2002-05-14 2004-01-08 Giudice Linda C. Endometrial genes in endometrial disorders
AU2003255355A1 (en) 2002-08-02 2004-02-25 Schering Aktiengesellschaft Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
AU2003303347A1 (en) 2002-12-21 2004-07-22 Universitat Leipzig Method and means for determining specific conditions or changes in the uterine epithelium and in the epithelium of other organs
US20060286555A1 (en) 2003-08-21 2006-12-21 Van Beuningen Marinus G J Microarray support for bioprobe synthesis
EP1670902A4 (en) 2003-09-08 2008-05-07 Univ Texas METHOD AND COMPOSITION FOR ENHANCING i IN VITRO /i EMBRYO DEVELOPMENT BY SUPPLEMENTING CULTURE MEDIUM WITH PROSTAGLANDIN OR A PROSTAGLANDIN ANALOG
CN1863905A (zh) 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物
EP1711618B1 (en) 2003-12-23 2010-08-04 Mount Sinai Hospital Corporation Methods for detecting markers associated with endometrial disease or phase
AU2005249504A1 (en) 2004-05-28 2005-12-15 Laboratoires Serono Sa Use of IL-17 in the treatment of fertility-related disorders
US20090111140A1 (en) * 2006-03-31 2009-04-30 Koninklijke Philips Electronics N.V. Systems and methods for cell measurement utilizing ultrashort t2*
JP2007278750A (ja) 2006-04-04 2007-10-25 Ono Pharmaceut Co Ltd プロスタグランジン類及びその類縁体の定量方法
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
US9259233B2 (en) * 2007-04-06 2016-02-16 Hologic, Inc. Method and device for distending a gynecological cavity
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2013166281A1 (en) * 2012-05-02 2013-11-07 Cedars-Sinai Medical Center Bi-functional compositions for targeting cells to diseased tissues and methods of using same
EP2348318A1 (en) 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Diagnostic method for endometrial receptivity
JP6204919B2 (ja) 2011-10-21 2017-09-27 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 調節性過排卵誘起後の患者の子宮内膜受容性を評価するための方法
AU2012346594B2 (en) 2011-11-30 2017-12-21 Agency For Science, Technology And Research GM1 ganglioside to Annexin V microparticle polypeptide ratio for biological monitoring
WO2014001244A1 (en) 2012-06-27 2014-01-03 Roche Diagnostics Gmbh MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
RU2515475C1 (ru) 2012-11-15 2014-05-10 Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте
JP6684263B2 (ja) 2014-03-21 2020-04-22 アイジェノミクス エセ．エレ． 子癇前症の早期検出
SMT202200155T1 (it) 2014-06-17 2022-05-12 Asherman Therapy S L Terapia con cellule staminali in patologie endometriali

Also Published As

Publication number Publication date
BR112016029558A2 (pt) 2017-08-22
US11129851B2 (en) 2021-09-28
MX377300B (es) 2025-03-07
US20170128492A1 (en) 2017-05-11
TR201910410T4 (tr) 2019-08-21
SMT202400270T1 (it) 2024-07-09
CN107073040A (zh) 2017-08-18
DK3569697T3 (da) 2022-04-04
JP2017522288A (ja) 2017-08-10
PL3158057T3 (pl) 2020-05-18
EP4012023B1 (en) 2024-05-15
DK3158057T3 (da) 2019-07-29
EP4012023C0 (en) 2024-05-15
EP4012023A1 (en) 2022-06-15
EP3569697B1 (en) 2022-01-05
PL3569697T3 (pl) 2022-07-04
HRP20220419T1 (hr) 2022-05-27
HUE058328T2 (hu) 2022-07-28
MX2016016756A (es) 2017-11-02
WO2015193737A1 (en) 2015-12-23
RU2017101147A (ru) 2018-07-17
SI3158057T1 (sl) 2019-10-30
EP3569697B8 (en) 2022-04-27
LT3158057T (lt) 2019-09-25
HRP20191240T1 (hr) 2019-11-01
CA2952559C (en) 2023-01-24
PL4012023T3 (pl) 2024-09-02
EP3158057A1 (en) 2017-04-26
CY1125938T1 (el) 2024-02-16
SI3569697T1 (sl) 2022-05-31
RU2725006C2 (ru) 2020-06-29
ES2983444T3 (es) 2024-10-23
HRP20240798T1 (hr) 2024-09-27
EP3158057B1 (en) 2019-04-17
RS63093B1 (sr) 2022-04-29
JP2020138984A (ja) 2020-09-03
RS65719B1 (sr) 2024-08-30
JP6920062B2 (ja) 2021-08-18
PT3569697T (pt) 2022-05-02
SMT201900400T1 (it) 2019-09-09
SMT202200155T1 (it) 2022-05-12
LT3569697T (lt) 2022-04-25
PT3158057T (pt) 2019-07-19
ES2736117T3 (es) 2019-12-26
EP3569697A1 (en) 2019-11-20
CN116747241A (zh) 2023-09-15
RS59210B1 (sr) 2019-10-31
HUE067463T2 (hu) 2024-10-28
CA2952559A1 (en) 2015-12-23
RU2017101147A3 (enExample) 2019-02-06
ES2910306T3 (es) 2022-05-12
AU2015275798B2 (en) 2021-03-25
HUE044823T2 (hu) 2019-11-28
AU2015275798A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
CY1125938T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες του ενδομητριου
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
EP3501459C0 (en) SURGICAL INSTRUMENT DESIGNED TO DETERMINE A FIRING TRAJECTORY
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CY1124767T1 (el) Rna για τη θεραπεια αυτοανοσων ασθενειων
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
UY35682A (es) Anticuerpos anti-activina a y usos de los mismos
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX375032B (es) Proteínas de unión y métodos para utilizarlas.
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
EA201792307A1 (ru) Способы репарации и регенерации тканей
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX383484B (es) Método para tratar el cáncer.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
NZ721835A (en) An osseointegrable device
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
MX2020003049A (es) Semaglutida en la terapia medica.
FR3003173B1 (fr) Substituts osseux greffes par des peptides mimetiques de la proteine humaine bmp-2.
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
SG11201909851SA (en) Peptide for inducing regeneration of tissue, and use thereof